# K122478: Modified Trevo Retriever

- Pathway: 510(k) (Traditional)
- Applicant: Concentric Medical, Inc.
- Decided: Oct 31, 2012 after 78 days
- Product code: NRY (Catheter, Thrombus Retriever)
- Device class: 2
- Regulation: 21 CFR 870.1250
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 5 generations back to K003410 (2001). 6 ancestors in all.
10 later devices descend from it; 3 cite it directly.
0 of 17 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K120961: Trevo Retriever, Concentric Medical, Inc. (2012)

## Most influential descendants
- K173452: EmboTrap ll Revascularization Device (2018), 4 descendants of its own
- K193063: EMBOTRAP III Revascularization Device (2020), 3 descendants of its own
- K132641: Modified Trevo Provue Retriever (2014), 3 descendants of its own
- K211338: EMBOTRAP III Revascularization Device (2021), 2 descendants of its own
- K212908: EmboTrap II Revascularization Device, EMBOTRAP III Revascularization Device (2021), 1 descendant of its own

## Indications for use
The Modified Trevo Retriever is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

Source page: https://510kreport.com/device/K122478
Methodology: https://510kreport.com/methodology